Interestingly, the combination of anti-VEGF + anti-PD-L1 (without IM) did not improve the overall survival of GBM-bearing mice (Figure 7O), consistent with the failed clinical trials combining PD-1/PD-L1 checkpoint inhibitors with antiangiogenic agents (NCT02337491, NCT03291314), highlighting the importance of imipramine for the observed efficacy of this novel triple therapy (Figure 7O). This evidence concerns the gene CD274 and glioblastoma.